Idorsia partners Jamjoom Pharma for QUVIVIQ

Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) for the distribution and commercialization of QUVIVIQ (daridorexant), its insomnia treatment, in Saudi Arabia and the Levant region. Under the terms, Idorsia will receive an upfront payment and is eligible for additional payments including royalties on net sales. Jamjoom Pharma will hold the marketing authorization in Saudi Arabia and manage regulatory, distribution, promotion, and commercialization activities across the region, while Idorsia will supply the finished drug product. The partnership aims to expand access to QUVIVIQ, a dual orexin receptor antagonist that improves sleep onset, maintenance, and daytime functioning. Idorsia shares rose 8.19% on the announcement.